Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO
- ID
- 47366
- Status
- summarized
- Published
- 17 Nov 2026, 9:58 PM
- Fetched
- 17 Nov 2026, 10:36 PM
- Provider
- CNBC Technology
- Category
- technology
- Original URL
- https://www.cnbc.com/2026/11/17/isomorphic-labs-series-c-ai-drug-discovery-.html
- Source URL
- https://www.cnbc.com/id/19854910/device/rss/rss.html
Summary
- Score
- 3.0
- Created
- 17 Nov 2026, 10:37 PM
- Tags
- Audience
- foundersai_ml_learners
What happened
Isomorphic Labs, the AI drug-discovery startup Demis Hassabis has led since it spun out of DeepMind in 2021, raised a $5 billion Series C announced 17 Nov 2026 — roughly three and a half months after Hassabis stepped back as CEO of Google DeepMind. The round was co-led by Greenoaks and Sequoia Capital alongside Andreessen Horowitz, with Alphabet also investing, and is earmarked for designing and developing new medicines with AI. The article notes 2026 has been a record funding year for drug-discovery startups, with OpenAI and Anthropic also investing in AI-for-medicine tools.
Why it matters
There is no technical or product change here for builders to act on: no model, API, benchmark, price, or availability was announced, only a capital raise and investor list. The one concrete signal is where late-stage AI money is landing in 2026 — a single $5B round into a wet-lab-adjacent vertical, with Alphabet investing in a company its former DeepMind CEO runs — which is context for founders deciding whether to pitch horizontal AI tooling or a regulated vertical like biotech. For a Malaysian dev or SaaS team, nothing in this text changes what you build this week.
Discussion angle
Isomorphic took $5B for AI drug discovery while most of the room is shipping thin wrappers on top of the same foundation models — worth asking whether vertical, capital-intensive AI bets like this are even addressable from Malaysia, or whether the realistic local play stays in services and tooling around these platforms.